TELO
Telomir Pharmaceuticals Inc
$
2.190
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.320
Open
2.185
VWAP
2.25
Vol
821.57K
Mkt Cap
65.18M
Low
2.175
Amount
1.85M
EV/EBITDA(TTM)
--
Total Shares
29.76M
EV
64.78M
EV/OCF(TTM)
--
P/S(TTM)
--
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Show More
Valuation Metrics
The current forward P/E ratio for Telomir Pharmaceuticals Inc (TELO.O) is -7.06, compared to its 5-year average forward P/E of -6.03. For a more detailed relative valuation and DCF analysis to assess Telomir Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.03
Current PE
-7.06
Overvalued PE
2.15
Undervalued PE
-14.21
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5990.86
Current PS
0.00
Overvalued PS
43595.39
Undervalued PS
-31613.67
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+14.18%
-2.19M
Operating Profit
FY2025Q1
YoY :
-65.15%
-2.18M
Net Income after Tax
FY2025Q1
YoY :
-69.57%
-0.07
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TELO News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
08:47:27
Telomir Pharmaceuticals announces new preclinical data on Telomir-1
2025-07-18 (ET)
2025-07-18
08:07:22
Telomir Pharmaceuticals announces new preclinical data on Telomir-1
2025-07-17 (ET)
2025-07-17
17:57:30
Telomir says data show Telomir-1 reversed epigenetic silencing
Sign Up For More Events
Sign Up For More Events
News
2.0
07-21BenzingaWhy Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
4.5
07-18BenzingaDow Falls Over 200 Points; 3M Earnings Top Views
4.5
07-18BenzingaUS Stocks Mixed; American Express Posts Upbeat Q2 Results
Sign Up For More News
People Also Watch
AISP
Airship AI Holdings Inc
5.670
USD
-0.70%
MMLP
Martin Midstream Partners LP
2.800
USD
0.00%
MRAM
Everspin Technologies Inc
6.360
USD
-2.75%
LARK
Landmark Bancorp Inc
26.190
USD
+0.31%
SKYX
SKYX Platforms Corp
1.140
USD
+2.70%
STIM
Neuronetics Inc
4.490
USD
+0.90%
CRBU
Caribou Biosciences Inc
2.280
USD
-3.80%
QUIK
Quicklogic Corp
6.210
USD
-3.57%
GGR
Gogoro Inc
0.393
USD
+3.69%
UEIC
Universal Electronics Inc
6.310
USD
-1.10%
FAQ
What is Telomir Pharmaceuticals Inc (TELO) stock price today?
The current price of TELO is 2.19 USD — it has decreased -4.37 % in the last trading day.
What is Telomir Pharmaceuticals Inc (TELO)'s business?
What is the price predicton of TELO Stock?
What is Telomir Pharmaceuticals Inc (TELO)'s revenue for the last quarter?
What is Telomir Pharmaceuticals Inc (TELO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Telomir Pharmaceuticals Inc (TELO)'s fundamentals?
How many employees does Telomir Pharmaceuticals Inc (TELO). have?